Home › Funds › Decheng Capital LLC › LYEL
Decheng Capital LLC position in LYEL
LYELL IMMUNOPHARMA INC · Health Care
Decheng Capital LLC reported holding 692,050 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$6.8M, representing 0.99% of its reported portfolio and ranking #8 among its reported holdings. Decheng Capital LLC has disclosed LYEL holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Decheng Capital LLC's LYEL position evolved
Decheng Capital LLC first disclosed a stake in LYEL in Q4 2024 at 11,909,341 shares (US$7.6M). The position peaked in Q4 2025 at 692,050 shares, worth US$21.3M. Across 8 filings, Decheng Capital LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 692,050 shares valued at US$6.8M. Notable position changes include a 95% trim in Q2 2025 (shares rose 84% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 11.91M | $7.62M | New |
| Q1 2025 | 11.91M | $6.41M | Hold |
| Q2 2025 | 595.47K | $5.26M | Reduce |
| Q3 2025 | 595.47K | $9.67M | Hold |
| Q4 2025 | 692.05K | $21.30M | Add |
| Q1 2026 | 692.05K | $13.88M | Hold |
| Q2 2026 | 692.05K | $9.72M | Hold |
| Q3 2026 | 692.05K | $6.78M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LYEL and 13F data
LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 27 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), GSK plc (US$14.8M), Almitas Capital LLC (US$8.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LYEL
- ARCH Venture Management, LLC 3.25M sh · $45.53M · Q2 2026
- GSK plc 1.51M sh · $14.81M · Q3 2026
- Almitas Capital LLC 581.41K sh · $8.17M · Q2 2026
- Orland Properties Ltd 754.70K sh · $7.39M · Q3 2026
- Foresite Capital Management V, LLC 476.39K sh · $6.69M · Q2 2026
- Opaleye Management Inc. 344.02K sh · $4.83M · Q2 2026
- venBio Partners LLC 337.70K sh · $4.74M · Q2 2026
- Alphabet Inc. 293.26K sh · $2.87M · Q3 2026
- HSG Holding Ltd 152.30K sh · $1.49M · Q3 2026
- Velan Capital Investment Management LP 105.00K sh · $1.48M · Q2 2026
- MIC Capital Management UK LLP 87.03K sh · $852.00K · Q3 2026
More on Decheng Capital LLC
FAQ
How long has Decheng Capital LLC held LYEL?
Decheng Capital LLC has disclosed LYEL holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Decheng Capital LLC's current position in LYEL?
As of Q3 2026, Decheng Capital LLC holds 692.05K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $6.78M, representing 0.99% of its reported portfolio and ranking #8.
Has Decheng Capital LLC been buying or selling LYEL?
In the latest 13F filing (Q3 2026), Decheng Capital LLC held unchanged its position in LYEL. The position peaked in Q4 2025 at 692.05K shares.
Which other funds hold LYEL?
Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Almitas Capital LLC, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.